Clover Health Investments (CLOV)
Clover Health Investments on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as hospital & medical service plans.
25.9M
Short interest
settlement 2026-10-15
5.3
Days to cover
-1.0 days vs prior
41.3%
Short share of volume
2026-10-28
22,868
Fails to deliver
settlement 2026-09-30
Wed 4 Nov
Next earnings
estimated date
-$4.2M
Insider flow, 90 days
0 buys, 18 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CLOV is 25,949,084 shares, up 2,502,901 shares over the last month. Over the last 48 readings it ranged from 11,895,643 shares (28 February 2025) to 54,071,005 shares (15 October 2025). At the reported average volume of 4.9M shares a day that is 5.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/clov" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 25,949,084 | +13.3% | 4,861,140 | 5.34 |
| 2026-09-30 | 22,900,620 | -2.3% | 3,632,140 | 6.30 |
| 2026-09-15 | 23,446,183 | -1.0% | 4,530,322 | 5.18 |
| 2026-08-31 | 23,677,399 | -9.4% | 3,446,264 | 6.87 |
| 2026-08-14 | 26,142,886 | -7.4% | 5,247,010 | 4.98 |
| 2026-07-31 | 28,237,098 | -1.8% | 3,932,455 | 7.18 |
| 2026-07-15 | 28,748,883 | +29.6% | 5,876,749 | 4.89 |
| 2026-06-30 | 22,184,648 | -10.7% | 7,916,464 | 2.80 |
| 2026-06-15 | 24,851,129 | -13.1% | 9,964,417 | 2.49 |
| 2026-05-29 | 28,596,652 | -23.5% | 8,252,151 | 3.47 |
| 2026-05-15 | 37,391,816 | -4.3% | 8,128,046 | 4.60 |
| 2026-04-30 | 39,092,575 | -3.7% | 6,110,277 | 6.40 |
| 2026-04-15 | 40,584,684 | +3.7% | 5,292,183 | 7.67 |
| 2026-03-31 | 39,120,656 | +2.0% | 5,959,741 | 6.56 |
| 2026-03-13 | 38,353,703 | -0.3% | 5,132,438 | 7.47 |
| 2026-02-27 | 38,465,992 | -6.4% | 4,957,104 | 7.76 |
| 2026-02-13 | 41,094,460 | +4.9% | 6,435,816 | 6.39 |
| 2026-01-30 | 39,183,403 | -2.5% | 6,633,106 | 5.91 |
| 2026-01-15 | 40,185,802 | +5.3% | 5,750,003 | 6.99 |
| 2025-12-31 | 38,170,121 | -4.4% | 4,173,677 | 9.15 |
| 2025-12-15 | 39,929,930 | -2.3% | 3,965,754 | 10.07 |
| 2025-11-28 | 40,852,910 | -6.0% | 4,979,039 | 8.20 |
| 2025-11-14 | 43,475,437 | +0.9% | 10,319,074 | 4.21 |
| 2025-10-31 | 43,089,212 | -20.3% | 11,515,668 | 3.74 |
| 2025-10-15 | 54,071,005 | +4.5% | 15,140,244 | 3.57 |
| 2025-09-30 | 51,735,259 | +5.0% | 5,129,378 | 10.09 |
| 2025-09-15 | 49,278,776 | +2.0% | 5,450,419 | 9.04 |
| 2025-08-29 | 48,326,485 | -3.9% | 4,390,454 | 11.01 |
| 2025-08-15 | 50,279,320 | +22.5% | 11,130,524 | 4.52 |
| 2025-07-31 | 41,040,883 | +13.4% | 8,709,445 | 4.71 |
| 2025-07-15 | 36,198,932 | -14.0% | 10,875,264 | 3.33 |
| 2025-06-30 | 42,080,972 | +88.9% | 13,722,502 | 3.07 |
| 2025-06-13 | 22,280,296 | +9.0% | 4,948,790 | 4.50 |
| 2025-05-30 | 20,442,735 | +31.2% | 6,227,698 | 3.28 |
| 2025-05-15 | 15,577,657 | +13.9% | 6,743,394 | 2.31 |
| 2025-04-30 | 13,675,507 | +10.6% | 4,497,230 | 3.04 |
| 2025-04-15 | 12,365,802 | +2.7% | 6,933,069 | 1.78 |
| 2025-03-31 | 12,044,344 | -8.3% | 4,421,736 | 2.72 |
| 2025-03-14 | 13,140,400 | +10.5% | 7,480,087 | 1.76 |
| 2025-02-28 | 11,895,643 | -22.4% | 5,866,123 | 2.03 |
| 2025-02-14 | 15,327,893 | +1.6% | 4,712,772 | 3.25 |
| 2025-01-31 | 15,081,636 | -8.1% | 7,131,354 | 2.11 |
| 2025-01-15 | 16,417,723 | +2.9% | 6,672,395 | 2.46 |
| 2024-12-31 | 15,956,062 | +9.0% | 4,810,285 | 3.32 |
| 2024-12-13 | 14,639,191 | -4.2% | 4,240,666 | 3.45 |
| 2024-11-29 | 15,276,865 | -7.1% | 4,416,705 | 3.46 |
| 2024-11-15 | 16,441,461 | -10.3% | 9,637,607 | 1.71 |
| 2024-10-31 | 18,329,869 | +16.4% | 6,961,219 | 2.63 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of CLOV volume is 41.3%, up 10.3 points over the last five sessions. Over the last 30 readings it ranged from 31.0% (21 October 2026) to 57.3% (24 September 2026). The latest reading is 4.3 points below the 30-session average of 45.6%, on 1.3M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 549K | 1.3M | 41.3% | 786 |
| 2026-10-27 | 629K | 1.3M | 49.1% | 75 |
| 2026-10-26 | 455K | 1.0M | 44.8% | 0 |
| 2026-10-23 | 551K | 1.5M | 36.2% | 1,863 |
| 2026-10-22 | 506K | 1.3M | 37.8% | 495 |
| 2026-10-21 | 472K | 1.5M | 31.0% | 857 |
| 2026-10-20 | 696K | 1.8M | 39.2% | 1,288 |
| 2026-10-19 | 678K | 1.8M | 38.2% | 23,556 |
| 2026-10-16 | 748K | 1.7M | 43.7% | 2,222 |
| 2026-10-15 | 826K | 1.6M | 52.7% | 154,961 |
| 2026-10-14 | 662K | 1.6M | 42.4% | 1,225 |
| 2026-10-13 | 582K | 1.5M | 38.2% | 474 |
| 2026-10-12 | 668K | 1.8M | 36.5% | 965 |
| 2026-10-09 | 2.5M | 5.2M | 48.1% | 3,413 |
| 2026-10-08 | 677K | 1.4M | 49.3% | 1,565 |
| 2026-10-07 | 838K | 1.9M | 43.9% | 350 |
| 2026-10-06 | 761K | 1.3M | 56.7% | 100 |
| 2026-10-05 | 1.0M | 2.1M | 49.8% | 1,675 |
| 2026-10-02 | 874K | 2.2M | 39.5% | 3,565 |
| 2026-10-01 | 884K | 1.7M | 52.1% | 174,341 |
| 2026-09-30 | 583K | 1.3M | 45.8% | 521 |
| 2026-09-29 | 469K | 1.0M | 46.1% | 2 |
| 2026-09-28 | 759K | 1.4M | 53.9% | 9,104 |
| 2026-09-25 | 718K | 1.5M | 47.3% | 0 |
| 2026-09-24 | 811K | 1.4M | 57.3% | 2 |
| 2026-09-23 | 635K | 1.5M | 42.8% | 2,095 |
| 2026-09-22 | 932K | 1.9M | 49.0% | 1,002 |
| 2026-09-21 | 632K | 1.1M | 55.0% | 213 |
| 2026-09-18 | 704K | 1.5M | 46.8% | 1,099 |
| 2026-09-17 | 786K | 1.5M | 52.7% | 496 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in CLOV is 22,868 shares, up 20,290 shares over the last settlement date. Over the last 30 readings it ranged from 100 shares (9 September 2026) to 105,995 shares (19 May 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 22,868 | $4.33 | $99K |
| 2026-09-24 | 2,578 | $4.57 | $12K |
| 2026-09-09 | 100 | $4.29 | $429 |
| 2026-09-04 | 5,979 | $4.26 | $25K |
| 2026-08-24 | 19,800 | $4.15 | $82K |
| 2026-08-21 | 192 | $4.10 | $787 |
| 2026-08-14 | 2,616 | $4.49 | $12K |
| 2026-08-10 | 10,000 | $4.76 | $48K |
| 2026-08-07 | 4,807 | $4.66 | $22K |
| 2026-08-04 | 5,364 | $4.33 | $23K |
| 2026-07-30 | 652 | $4.23 | $3K |
| 2026-07-20 | 8,209 | $4.62 | $38K |
| 2026-07-17 | 10,040 | $4.40 | $44K |
| 2026-07-13 | 10,500 | $4.44 | $47K |
| 2026-07-02 | 6,339 | $5.39 | $34K |
| 2026-07-01 | 335 | $5.24 | $2K |
| 2026-06-30 | 17,921 | $5.31 | $95K |
| 2026-06-24 | 313 | $5.06 | $2K |
| 2026-06-22 | 49,543 | $5.00 | $248K |
| 2026-06-17 | 500 | $4.94 | $2K |
| 2026-06-15 | 10,146 | $4.73 | $48K |
| 2026-06-10 | 699 | $4.29 | $3K |
| 2026-06-09 | 49,130 | $3.92 | $193K |
| 2026-06-08 | 8,008 | $3.83 | $31K |
| 2026-06-03 | 18,274 | $3.73 | $68K |
| 2026-06-01 | 500 | $3.98 | $2K |
| 2026-05-29 | 4,611 | $4.18 | $19K |
| 2026-05-28 | 765 | $3.59 | $3K |
| 2026-05-26 | 490 | $3.55 | $2K |
| 2026-05-19 | 105,995 | $3.39 | $359K |
Insider trades
SEC Form 4, newest first. JSONInsiders at CLOV reported 18 open-market sells worth $4.2M in the last 90 days and no open-market buys. Latest filing: Soares Karen (Chief Legal Officer) on 2026-10-20.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Soares Karen | Chief Legal Officer | Sell | 19K | $4.66 | $90K | 1.6M |
| 2026-10-19 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 4K | $4.41 | $18K | 2.8M |
| 2026-10-15 | Toy Andrew | Chief Executive Officer | Sell | 62K | $4.68 | $291K | 9.1M |
| 2026-10-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 18K | $4.68 | $86K | 2.8M |
| 2026-10-15 | Wai Conrad | CEO, Counterpart Health | Sell | 24K | $4.68 | $111K | 1.0M |
| 2026-10-15 | THORNTON JOSEPH CLAY | Interim CFO | Sell | 5K | $4.68 | $21K | 1.2M |
| 2026-10-15 | Soares Karen | Chief Legal Officer | Sell | 15K | $4.68 | $69K | 1.6M |
| 2026-10-07 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 2K | $4.63 | $9K | 2.8M |
| 2026-10-05 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 9K | $4.42 | $39K | 2.8M |
| 2026-10-01 | Toy Andrew | Chief Executive Officer | Sell | 319K | $4.19 | $1.3M | 9.1M |
| 2026-09-30 | Miller Brian James | Director | Grant | 12K | $0.00 | $0 | 12K |
| 2026-09-30 | Torricelli Robert G | Director | Grant | 12K | $0.00 | $0 | 187K |
| 2026-09-17 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 2K | $4.56 | $9K | 2.8M |
| 2026-09-16 | OLDAKOWSKI JOSEPH FRANK | VP OF FINANCE AND CONTROLLER | Sell | 3K | $4.64 | $15K | 276K |
| 2026-09-15 | Wai Conrad | CEO, Counterpart Health | Sell | 300K | $4.72 | $1.4M | 1.2M |
| 2026-09-15 | Soares Karen | Chief Legal Officer | Sell | 7K | $4.78 | $33K | 1.6M |
| 2026-09-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 9K | $4.78 | $44K | 2.8M |
| 2026-09-14 | OLDAKOWSKI JOSEPH FRANK | VP OF FINANCE AND CONTROLLER | Sell | 20K | $5.16 | $103K | 279K |
| 2026-08-17 | THORNTON JOSEPH CLAY | Interim CFO | Sell | 18K | $4.39 | $78K | 1.2M |
| 2026-08-12 | Soares Karen | Chief Legal Officer | Grant | 109K | $0.00 | $0 | 1.6M |
| 2026-08-12 | THORNTON JOSEPH CLAY | Interim CFO | Grant | 54K | $0.00 | $0 | 1.3M |
| 2026-08-10 | Toy Andrew | Chief Executive Officer | Sell | 88K | $4.65 | $408K | 9.5M |
| 2026-07-20 | Soares Karen | Chief Legal Officer | Sell | 52K | $4.51 | $233K | 1.5M |
| 2026-07-17 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 5K | $4.53 | $22K | 2.8M |
| 2026-07-15 | Toy Andrew | Chief Executive Officer | Sell | 63K | $4.67 | $293K | 9.5M |
| 2026-07-15 | Wai Conrad | CEO, Counterpart Health | Sell | 24K | $4.67 | $113K | 1.1M |
| 2026-07-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 13K | $4.67 | $61K | 2.8M |
| 2026-07-15 | Soares Karen | Chief Legal Officer | Sell | 11K | $4.67 | $49K | 1.6M |
| 2026-07-15 | THORNTON JOSEPH CLAY | Interim CFO | Sell | 5K | $4.67 | $22K | 1.2M |
| 2026-07-08 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 2K | $4.68 | $11K | 2.8M |
| 2026-07-06 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 6K | $5.26 | $33K | 2.8M |
| 2026-07-01 | Toy Andrew | Chief Executive Officer | Sell | 313K | $5.32 | $1.7M | 9.6M |
| 2026-06-17 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 2K | $4.78 | $11K | 2.8M |
| 2026-06-16 | OLDAKOWSKI JOSEPH FRANK | VP OF FINANCE AND CONTROLLER | Sell | 12K | $4.86 | $59K | 299K |
| 2026-06-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 6K | $4.61 | $29K | 2.8M |
| 2026-06-15 | Soares Karen | Chief Legal Officer | Sell | 5K | $4.61 | $22K | 1.6M |
| 2026-06-11 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 7K | $4.91 | $36K | 2.8M |
| 2026-05-28 | Wai Conrad | CEO, Counterpart Health | Sell | 220K | $3.99 | $879K | 1.4M |
| 2026-05-18 | Edwards Carladenise Armbrister | Director | Sell | 67K | $3.42 | $230K | 285K |
| 2026-05-16 | THORNTON JOSEPH CLAY | Interim CFO | Tax withholding | 17K | $3.47 | $59K | 1.2M |
| 2026-05-13 | Priest Brady Patrick | CEO of Clover Care Services | Sell | 98K | $3.52 | $345K | 2.0M |
| 2026-05-08 | Toy Andrew | Chief Executive Officer | Tax withholding | 86K | $2.82 | $242K | 9.9M |
| 2026-04-18 | Priest Brady Patrick | CEO of Clover Care Services | Tax withholding | 36K | $2.19 | $79K | 2.1M |
| 2026-04-15 | Soares Karen | Chief Legal Officer | Tax withholding | 10K | $2.04 | $21K | 1.6M |
| 2026-04-15 | Wai Conrad | CEO, Counterpart Health | Tax withholding | 23K | $2.04 | $48K | 1.2M |
| 2026-04-15 | Priest Brady Patrick | CEO of Clover Care Services | Tax withholding | 15K | $2.04 | $32K | 2.2M |
| 2026-04-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 13K | $2.04 | $26K | 2.9M |
| 2026-04-15 | Toy Andrew | Chief Executive Officer | Tax withholding | 61K | $2.04 | $124K | 10.0M |
| 2026-04-15 | THORNTON JOSEPH CLAY | Interim CFO | Tax withholding | 4K | $2.04 | $8K | 1.2M |
| 2026-04-03 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 6K | $1.72 | $11K | 2.9M |
| 2026-04-01 | Soares Karen | Chief Legal Officer | Grant | 383K | $0.00 | $0 | 1.6M |
| 2026-04-01 | Wai Conrad | CEO, Counterpart Health | Grant | 268K | $0.00 | $0 | 1.2M |
| 2026-04-01 | Priest Brady Patrick | CEO of Clover Care Services | Grant | 191K | $0.00 | $0 | 2.2M |
| 2026-04-01 | Reynoso Jamie L. | CEO, Medicare Advantage | Grant | 159K | $0.00 | $0 | 2.9M |
| 2026-04-01 | Toy Andrew | Chief Executive Officer | Tax withholding | 310K | $1.76 | $545K | 10.1M |
| 2026-04-01 | Toy Andrew | Chief Executive Officer | Grant | 956K | $0.00 | $0 | 10.4M |
| 2026-03-18 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 6K | $1.91 | $11K | 2.7M |
| 2026-03-15 | Soares Karen | General Counsel & Secretary | Tax withholding | 5K | $1.98 | $9K | 1.2M |
| 2026-03-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 6K | $1.98 | $12K | 2.7M |
| 2026-03-14 | Wai Conrad | CEO, Counterpart Health | Tax withholding | 100K | $1.98 | $198K | 926K |
| 2026-03-14 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 9K | $1.98 | $18K | 2.7M |
| 2026-03-04 | Priest Brady Patrick | CEO of Home Care | Sell | 175K | $2.17 | $380K | 2.0M |
| 2026-02-14 | Soares Karen | General Counsel & Secretary | Tax withholding | 6K | $2.02 | $12K | 1.2M |
| 2026-02-08 | Toy Andrew | Chief Executive Officer | Tax withholding | 86K | $2.13 | $183K | 9.4M |
| 2026-01-29 | Kuipers Peter J. | Chief Financial Officer | Tax withholding | 157K | $2.31 | $362K | 5.8M |
| 2026-01-20 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 5K | $2.58 | $12K | 2.7M |
| 2026-01-18 | Priest Brady Patrick | CEO of Home Care | Tax withholding | 37K | $2.54 | $94K | 2.2M |
| 2026-01-15 | Toy Andrew | Chief Executive Officer | Tax withholding | 61K | $2.81 | $171K | 9.5M |
| 2026-01-15 | Soares Karen | General Counsel & Secretary | Tax withholding | 12K | $2.81 | $33K | 1.2M |
| 2026-01-15 | Wai Conrad | CEO, Counterpart Health | Tax withholding | 26K | $2.81 | $73K | 1.0M |
| 2026-01-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 15K | $2.81 | $41K | 2.7M |
| 2026-01-15 | Priest Brady Patrick | CEO of Home Care | Tax withholding | 18K | $2.81 | $51K | 2.2M |
| 2026-01-07 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 2K | $2.53 | $5K | 2.8M |
| 2026-01-07 | Garipalli Vivek | Director, 10% owner | Tax withholding | 1.7M | $2.59 | $4.3M | 1.9M |
| 2026-01-07 | Garipalli Vivek | Director, 10% owner | Exercise or conversion | 1.7M | $0.00 | $0 | 3.5M |
| 2026-01-06 | Kouzoukas Demetrios L. | Director | Grant | 79K | $0.00 | $0 | 606K |
| 2026-01-06 | Edwards Carladenise Armbrister | Director | Grant | 79K | $0.00 | $0 | 353K |
| 2026-01-06 | Loengard Anna U | Director | Grant | 79K | $0.00 | $0 | 527K |
| 2026-01-06 | Robinson William G Jr | Director | Grant | 79K | $0.00 | $0 | 598K |
| 2026-01-06 | Tran Thomas L | Director | Grant | 79K | $0.00 | $0 | 180K |
| 2026-01-03 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 8K | $2.41 | $20K | 2.8M |
| 2026-01-01 | Toy Andrew | Chief Executive Officer | Tax withholding | 268K | $2.35 | $630K | 9.6M |
| 2025-12-18 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 5K | $2.61 | $13K | 2.8M |
| 2025-12-15 | Soares Karen | General Counsel & Secretary | Tax withholding | 6K | $2.70 | $17K | 1.2M |
| 2025-12-15 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 9K | $2.70 | $23K | 2.8M |
| 2025-12-14 | Wai Conrad | CEO, Counterpart Health | Tax withholding | 98K | $2.70 | $266K | 1.1M |
| 2025-12-14 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 13K | $2.70 | $34K | 2.8M |
| 2025-11-14 | Soares Karen | General Counsel & Secretary | Tax withholding | 7K | $2.47 | $18K | 1.2M |
| 2025-11-08 | Toy Andrew | Chief Executive Officer | Tax withholding | 86K | $2.67 | $228K | 9.8M |
| 2025-11-04 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 30K | $3.58 | $109K | 2.8M |
| 2025-10-31 | Soares Karen | General Counsel & Secretary | Tax withholding | 38K | $3.53 | $134K | 1.2M |
| 2025-10-31 | Soares Karen | General Counsel & Secretary | Tax withholding | 132K | $3.53 | $464K | 1.3M |
| 2025-10-31 | Wai Conrad | CEO, Counterpart Health | Tax withholding | 28K | $3.53 | $99K | 1.2M |
| 2025-10-31 | Wai Conrad | CEO, Counterpart Health | Tax withholding | 96K | $3.53 | $340K | 1.2M |
| 2025-10-31 | Priest Brady Patrick | CEO of Home Care | Tax withholding | 25K | $3.53 | $89K | 2.2M |
| 2025-10-31 | Priest Brady Patrick | CEO of Home Care | Tax withholding | 87K | $3.53 | $306K | 2.3M |
| 2025-10-31 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 30K | $3.53 | $104K | 2.8M |
| 2025-10-31 | Reynoso Jamie L. | CEO, Medicare Advantage | Tax withholding | 102K | $3.53 | $360K | 2.9M |
| 2025-10-29 | Kuipers Peter J. | Chief Financial Officer | Tax withholding | 217K | $3.64 | $791K | 5.9M |
| 2025-10-18 | Priest Brady Patrick | CEO of Home Care | Tax withholding | 48K | $2.71 | $131K | 2.3M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON27 Form 144 notices on file for CLOV worth $11.0M at the prices reported; 10 in the last 90 days worth $6.5M. Latest: KAREN SOARES filed on 2026-10-20 to sell 19,275 shares ($86K) from 2026-10-20.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-20 | KAREN SOARESOfficer | 19K | $86K | 0.004% | 2026-10-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-19 | JAMIE REYNOSOOfficer | 4K | $18K | 0.001% | 2026-10-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-07 | JAMIE REYNOSOOfficer | 2K | $9K | 0.000% | 2026-10-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-24 | BRADY PRIESTFormer Officer | 141K | $631K | 0.032% | 2026-09-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-17 | JAMIE REYNOSOOfficer | 2K | $9K | 0.000% | 2026-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | BRADY PRIESTFormer Officer | 215K | $1000K | 0.049% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-14 | JOSEPH OLDAKOWSKIOfficer | 20K | $103K | 0.005% | 2026-09-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-31 | BRADY PRIESTOfficer | 74K | $305K | 0.017% | 2026-08-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-14 | BRADY PRIESTOfficer | 475K | $2.2M | 0.109% | 2026-08-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-07 | BRADY PRIESTOfficer | 442K | $2.1M | 0.101% | 2026-08-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-20 | KAREN SOARESOfficer | 52K | $239K | 0.012% | 2026-07-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-17 | JAMIE REYNOSOOfficer | 5K | $21K | 0.001% | 2026-07-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-08 | JAMIE REYNOSOOfficer | 2K | $12K | 0.001% | 2026-07-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-17 | JAMIE REYNOSOOfficer | 2K | $12K | 0.001% | 2026-06-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | JAMIE REYNOSOOfficer | 7K | $36K | 0.002% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-18 | CARLADENISE A EDWARDSDirector | 67K | $229K | 0.016% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-14 | Kuipers Peter J.former CFO | 886K | $3.1M | 0.206% | 2026-05-14 | Fidelity Investments |
| 2026-05-13 | BRADY PRIESTOfficer | 98K | $345K | 0.023% | 2026-05-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-18 | JAMIE REYNOSOOfficer | 6K | $11K | 0.001% | 2026-03-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | BRADY PRIESTOfficer | 175K | $379K | 0.041% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-20 | JAMIE REYNOSOOfficer | 5K | $12K | 0.001% | 2026-01-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-07 | JAMIE REYNOSOOfficer | 2K | $5K | 0.000% | 2026-01-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-18 | JAMIE REYNOSOOfficer | 5K | $13K | 0.001% | 2025-12-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-04 | JAMIE REYNOSOOfficer | 30K | $112K | 0.007% | 2025-11-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-17 | JAMIE REYNOSOOfficer | 17K | $45K | 0.004% | 2025-10-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-07 | JAMIE REYNOSOOfficer | 2K | $5K | 0.000% | 2025-10-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-17 | JAMIE REYNOSOOfficer | 5K | $15K | 0.001% | 2025-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSONNo holder on file reports 5% or more of CLOV in its latest filing.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding CLOV at their latest 13F. JSON6 of the 30 tracked managers held CLOV at their latest 13F, $50.3M in total at quarter-end prices. Renaissance Technologies is the largest at $14.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 2.8M | $14.7M | 0.02% | -594K |
| Citadel Advisors | 2026-06-30 | 2.2M | $11.3M | 0.00% | +285K |
| D. E. Shaw & Co. | 2026-06-30 | 2.0M | $10.3M | 0.00% | +1.9M |
| Millennium Management | 2026-06-30 | 1.1M | $5.8M | 0.00% | -56K |
| Point72 Asset Management | 2026-06-30 | 1.1M | $5.6M | 0.01% | +567K |
| AQR Capital Management | 2026-06-30 | 488K | $2.6M | 0.00% | +383K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Clover Health Investments reported revenue of $743.2M, up 55.6% from the same quarter a year earlier, and net income of $28.0M (0.05 diluted EPS). In FY 2025 it generated -$66.9M of operating cash flow and spent $18.3M on buybacks.
- Equity
- $376.3M
- Total assets
- $720.3M
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $743.2M | $28.0M | 3.8% | 0.05 |
| Q1 FY 2026 | 2026-03-31 | $749.2M | $27.3M | 3.6% | 0.05 |
| Q4 FY 2025derived | 2025-12-31 | $487.7M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $496.6M | -$24.4M | -4.9% | n/a |
| Q2 FY 2025 | 2025-06-30 | $477.6M | -$10.6M | -2.2% | -0.02 |
| Q1 FY 2025 | 2025-03-31 | $462.3M | -$1.3M | -0.3% | 0.00 |
| Q4 FY 2024derived | 2024-12-31 | $337.0M | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $331.0M | -$9.2M | -2.8% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.92B | -$85.5M | -$66.9M | $2.0M | $18.3M | n/a |
| FY 2024 | 2024-12-31 | $1.37B | -$43.0M | $34.8M | $1.6M | $1.8M | n/a |
| FY 2023 | 2023-12-31 | $1.26B | -$213.4M | -$144.7M | $584K | $0 | n/a |
| FY 2022 | 2022-12-31 | $1.10B | -$338.8M | -$203.9M | $4.5M | $0 | n/a |
| FY 2021 | 2021-12-31 | $1.47B | -$587.8M | -$282.3M | $723K | $147K | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30.
What this page is
Clover Health Investments in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Clover Health Investments (CLOV), SEC CIK 1801170, listed on Nasdaq, classified by the SEC as hospital & medical service plans. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-20.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-03-26.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-20.JSON and CSV
- Company record
- EDGAR filing index for CIK 1801170Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as hospital & medical service plans
Other company pages
Datasets
Frequently Asked Questions
How much of CLOV is sold short?
25,949,084 shares were held short at the 2026-10-15 settlement, 5.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CLOV's daily short volume?
On 2026-10-28, 548,952 of the 1,329,593 CLOV shares reported to FINRA were sold short, 41.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CLOV have fails to deliver?
The SEC's latest file shows 22,868 CLOV shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are CLOV insiders buying or selling?
Insiders at CLOV reported 18 open-market sells worth $4.2M in the last 90 days and no open-market buys. Latest filing: Soares Karen (Chief Legal Officer) on 2026-10-20.
Have CLOV insiders filed to sell?
27 Form 144 notices on file for CLOV worth $11.0M at the prices reported; 10 in the last 90 days worth $6.5M. Latest: KAREN SOARES filed on 2026-10-20 to sell 19,275 shares ($86K) from 2026-10-20.
Who owns 5% or more of CLOV?
No holder on file reports 5% or more of CLOV in its latest filing.
What did CLOV report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Clover Health Investments reported revenue of $743.2M, up 55.6% from the same quarter a year earlier, and net income of $28.0M (0.05 diluted EPS). In FY 2025 it generated -$66.9M of operating cash flow and spent $18.3M on buybacks.
Which tracked 13F managers own CLOV?
6 of the 30 tracked 13F managers held CLOV shares at their latest filing, $50.3M in all. The largest: Renaissance Technologies (2.8M shares, $14.7M), Ken Griffin's Citadel Advisors (2.2M shares, $11.3M), D. E. Shaw & Co. (2.0M shares, $10.3M), Izzy Englander's Millennium Management (1.1M shares, $5.8M), Steve Cohen's Point72 Asset Management (1.1M shares, $5.6M), Cliff Asness's AQR Capital Management (488K shares, $2.6M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.